PPME1 Human

PPME1 catalyzes the demethylation of the PP2A catalytic subunit, which is a reversible post-translational modification. This demethylation process is essential for the regulation of PP2A activity. By demethylating PP2A, PPME1 influences the enzyme’s ability to interact with regulatory subunits and other proteins, thereby modulating its function .

PPME1 supports the ERK pathway through the dephosphorylation of regulatory proteins, which is vital for cell cycle progression and other cellular functions . Additionally, PPME1 has been implicated in the progression of malignant gliomas, a type of brain tumor .

Recombinant PPME1 is a form of the enzyme that is produced through recombinant DNA technology. This involves inserting the PPME1 gene into an expression system, such as E. coli, to produce the protein in large quantities. Recombinant PPME1 is used in various research applications, including studying its role in cellular processes and its potential as a therapeutic target .

PPME1 is associated with several diseases, including Diabetes Insipidus, Nephrogenic, 2, Autosomal, and Waardenburg Syndrome, Type 4C . Its role in the regulation of PP2A makes it a potential target for therapeutic interventions in diseases where PP2A activity is dysregulated.

Recombinant PPME1 is widely used in research to understand its function and regulation. It is utilized in blocking assays and other experimental setups to study protein interactions and post-translational modifications . The availability of recombinant PPME1 allows researchers to investigate its role in various cellular pathways and its potential implications in disease.